摘要
Abstract
Objective To explore the protective effect and mechanism of magnesium isoglycyrrhizinate on liver injury after hepatic artery chemoembolization(TACE)in patients with primary liver cancer.Methods Ninety-eight patients with primary liver cancer who received TACE treatment in Jilin Provincial People's Hospital from April 2021 to April 2024 were selected and divided into control group and observation group according to random number table method,with 49 cases in each group.The control group received reduced glutathione injection and vitamin C injection 1 day before and 3 days after TACE,respectively,and the observation group received magnesium isoglycyrrhizinate injection intravenously at the same time point on the basis of the control group.The levels of liver function indexes,inflammatory factors,oxidative stress indexes and drug-related adverse reactions during treatment were compared between the two groups.Results One week after operation,the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),alkaline phosphatase(ALP)and total bilirubin(TBIL)in observation group were lower than those in control group(P＜0.05).The levels of tumor necrosis factor α(TNF-α),nuclear factor κB(NF-κB)and interleukin-6(IL-6)in observation group were lower than those in control group(P＜0.05).The level of malondialdehyde(MDA)in observation group was lower than that in control group(P＜0.05),and the level of superoxide dismutase(SOD)was higher than that in control group(P＜0.05).No adverse reactions such as nausea,vomiting,hepatitis,fever and infection occurred in both groups from the beginning of treatment to one week after surgery.Conclusion Adding magnesium isoglycyrrhizinate to the liver protection regimen after TACE in patients with primary liver cancer can actively optimize the liver function of the patients,which may be related to the mechanism of inhibiting inflammation and alleviating oxidative stress.关键词
原发性肝癌/异甘草酸镁/肝损伤/炎症因子/氧化应激Key words
Primary liver cancer/Magnesium isoglycyrrhizinate/Liver injury/Inflammatory factors/Oxidative stress分类
医药卫生
